News summary

Allergan brings skin longevity into the GLP-1 era

Source: Longevity Technology • Published: 30 Sept 2026, 16:50

Summarized by Masters of Longevity from Longevity Technology.

Reports on how dermatology R&D is applying hallmarks-of-aging frameworks and real-world skin data from people using GLP-1 weight-loss drugs to shape skincare science and trials.

Allergan brings skin longevity into the GLP-1 era
Key Takeaways
  • Allergan Aesthetics introduced the FACTS Principles to standardize exosome skincare formulation, analysis, and safety.
  • Two small studies found investigator-assessed improvements in dryness, tone, crepiness, and texture during GLP-1–associated weight loss.
  • Participants reported perceived facial skin looking about 10 years younger after four weeks of topical regimen use in one study.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.